Lv1
40 积分 2022-11-02 加入
Breast cancer in China
5天前
已完结
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
11天前
已完结
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
18天前
已完结
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
20天前
已完结
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
1个月前
已完结
Efficacy and safety of adjuvant therapies in older patients with breast cancer: a systematic review and meta-analysis of real-world data
2个月前
已完结
Bone Metastasis of Breast Cancer
2个月前
已完结
Bone Metastasis of Breast Cancer
2个月前
已关闭
Capivasertib en association au fulvestrant dans le cancer du sein localement avancé ou métastatique RH+ HER2– avec une altération de PIK3CA, AKT1 ou PTEN, après une première ligne d’hormonothérapie
3个月前
已关闭
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
3个月前
已完结
皖公网安备34019202002308
